The determination of biosimilarity margin and the assessment of biosimilarity for an (m+1)-arm parallel design

Junhui Park and Seung-Ho Kang

Communications in Statistics - Theory and Methods, 2022, vol. 51, issue 2, 387-403

Abstract: One of the key issues in biosimilar phase III clinical trials is the determination of biosimilarity margins. Although biological products generally have high product variability, it is not reflected in the methods most commonly used for determining biosimilarity margins. In order to take into account high product variability, in this paper, we propose (m+1)-arm parallel design, which consists of one biosimilar product group and m reference product groups. Because there are m reference product groups, we can estimate the between-batch variation of reference products using a random effect model. A statistical testing procedure appropriate for assessing biosimilarity using (m+1)-arm parallel design is developed based on asymptotic theory. From simulation studies, we conclude that at least three reference product batches are needed for practical use of the proposed method.

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1080/03610926.2020.1749664 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:lstaxx:v:51:y:2022:i:2:p:387-403

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/lsta20

DOI: 10.1080/03610926.2020.1749664

Access Statistics for this article

Communications in Statistics - Theory and Methods is currently edited by Debbie Iscoe

More articles in Communications in Statistics - Theory and Methods from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().